‣ 1\. Voluntarily participate in the study and sign the informed consent form; 2, Aged ≥18 years (calculated as of the date of signing the informed consent form); 3 .Diagnosed with hepatocellular carcinoma (HCC) by clinical or pathological means; 4. Barcelona Clinic Liver Cancer (BCLC) stage C, with vascular/bile duct invasion or distant metastasis (excluding cases with Vp4-type tumor thrombus); 5. No prior systemic therapy for HCC; or progression or residual lesions following prior local therapy for HCC (including but not limited to surgery, ablation, radiotherapy, or transarterial chemoembolization \[TACE\]), with an interval of at least one month between the last local treatment and enrollment; 6. ECOG Performance Status (PS) score of 0-1 and Child-Pugh grade A or grade B with a score of 7; 7. No history of autoimmune disease; 8. An expected survival time of ≥3 months; 9. At least one measurable lesion (per RECIST v1.1 criteria, the longest diameter of the measurable lesion on spiral CT scan must be ≥10 mm or the short axis of enlarged lymph nodes must be ≥15 mm; lesions previously treated locally can be considered target lesions if progression is confirmed per RECIST v1.1 criteria); 10. Sufficient hematologic, hepatic, and renal function, with laboratory tests within the following parameters performed within one week prior to enrollment:

• Neutrophil count ≥1.5×10\^9/L;

⁃ Platelet count ≥75×10\^9/L; ③ Hemoglobin ≥90 g/L;

‣ Serum ALT and AST ≤5×upper limit of normal (ULN);

∙ Serum creatinine ≤1.5×ULN;

• International Normalized Ratio (INR) \<2.3, or prothrombin time ≤ULN+6 seconds;

⁃ Albumin ≥30 g/L; ⑧ Total bilirubin ≤3×ULN. 11.Women of childbearing potential must have a negative serum or urine pregnancy test within seven days prior to study enrollment, must not be breastfeeding, and must agree to use contraceptive measures during the study and for six months after its conclusion; men must agree to use contraceptive measures during the study and for six months after its conclusion.